Regolamento (UE) 2024/2865

Regolamento (UE) 2024/2865 / Modifiche Regolamento CLP
ID 22963 | 20.11.2024
Regolamento (UE) 2024/2865 del Parlamento europeo e del Consiglio, del 23 ottobre 2024, che modifica il regolamento (CE) n. 1...

Compliance with good manufacturing practice (“GMP”) is mandatory for all medicinal products that have been granted a marketing authorisation. Likewise, the manufacture of investigational medicinal products must be in accordance with GMP. Advanced therapy medicinal products that are administered to patients under Article 3 of Directive 2001/83/EC (so called “hospital exemption”) must be manufactured under equivalent quality standards to the manufacturing of advanced therapy medicinal products with a marketing authorisation.
Article 5 of Regulation (EC) No 1394/2007 mandates the Commission to draw up guidelines on good manufacturing practice specific to advanced therapy medicinal products ("ATMPs"). Article 63(1) of Regulation (EU) No 536/2014 also empowers the Commission to adopt and publish detailed guidelines on good manufacturing practice applicable to investigational medicinal products.
EC 22.11.2017
EudraLex 22.11.2017

ID 22963 | 20.11.2024
Regolamento (UE) 2024/2865 del Parlamento europeo e del Consiglio, del 23 ottobre 2024, che modifica il regolamento (CE) n. 1...

ID 21585 | 27.03.2024 / In allegato
Il Ministero della Salute, in qualità di punto di contatto nazionale per la ...

ID 18883 | 02.02.2023 / Note complete in allegato
Le informazioni concernenti la composizione delle miscele pericolose...
Testata editoriale iscritta al n. 22/2024 del registro periodici della cancelleria del Tribunale di Perugia in data 19.11.2024